CompanyIntelligence | King Pharmaceuticals Inc.

The Consus Group provides critical intelligence for the
business, investor, and legal communities.

Documents can be downloaded immediately after purchase. Complete your order by clicking the Add-to-Cart button.

$40	Subscribers Preview	2003	15-Day Extension for Form 10-K Filed by King Pharmaceuticals	King Pharmaceuticals Inc.
$51	Subscribers Preview	2001	Agreement for Purchase and Sale of Assets	King Pharma; Novavax	Hogan & Hartson
$41	Subscribers	2000	American Home Products and King Pharmaceuticals Finalize Co-Promotion Arrangement for Altace(R)	King Pharmaceuticals Inc.	Wyeth
$88	Subscribers Preview	2003	Annual Report to Shareholders	AMD; Aeropostale; AFLAC	Agrium 2 3 4 5 6 2 3 4 5 6
$80	Subscribers Preview	2003	Annual Report to Shareholders	Adaptec; Aeroflex; Affymetrix	AFLAC 2 3 4 5 6 2 3 4 5 6
$99	Subscribers Preview	2003	Annual Report to Shareholders	AMD; Aeropostale; AFLAC	Agrium 2 3 4 5 6 2 3 4 5 6
$99	Subscribers Preview	2003	Annual Report to Shareholders	Adaptec; Aeroflex; Affymetrix	AFLAC 2 3 4 5 6 2 3 4 5 6
$34	Subscribers	2003	Barr Reports Third Quarter 2003 EPS of $0.66	Barr Pharma; Cephalon; King Pharma	Shire Labs; Wyeth
$43	Subscribers	2000	Draft Talking Points	King Pharmaceuticals Inc.
$37	Subscribers Preview	2003	Elan Announces Agreement with King to Settle Lawsuit	Elan; King Pharma	Wyeth
$38	Subscribers Preview	2004	Elan Announces Continued Progress	Elan Pharma S.A.; Elan	King Pharma
$33	Subscribers Preview	2003	Elan Announces Publication of Its Shareholder Circular and Sets Date for Special Shareholders Meeting March 18, 2003	Elan Corp., plc	King Pharmaceuticals Inc.
$38	Subscribers Preview	2003	Elan Announces Receipt of FTC Inquiry Relating to Skelaxin	Elan Corp., plc	King Pharmaceuticals Inc.
$41	Subscribers Preview	2003	Elan Announces Receipt of FTC Letter Regarding Skelaxin	Elan Corp., plc	King Pharmaceuticals Inc.
$37	Subscribers Preview	2003	Elan Completes Sale of Its Primary Care Franchise After Receiving Shareholder Approval	Elan; King Pharma	Wyeth
$40	Subscribers Preview	2003	Elan Files Suit Against King Pharmaceuticals Seeking to Compel the Timely Closing of the Sale of Elan's Primary Care Assets	Elan Corp., plc	King Pharmaceuticals Inc.
$41	Subscribers Preview	2003	Elan First Quarter 2003 Financial Results and Recovery Plan Update	Elan; King Pharma; Ligand Pharma	Wyeth; Duke
$32	Subscribers Preview	2003	Elan Receives Shareholder Approval for the Sale of Its Primary Care Franchise and for the Disapplication of Pre-Emption Rights	Elan Corp., plc	King Pharmaceuticals Inc.
$37	Subscribers Preview	2004	Elan Reports First Quarter 2004 Financial Results	Biogen Idec; Eisai; Elan	King Pharma; Ligand Pharma; Vernalis
$42	Subscribers Preview	2003	Elan Reports Second Quarter 2003 Financial Results	Elan Pharmaceutical Investments III, Ltd.; Biogen; Elan	King Pharma; Ligand Pharma; Wyeth